BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a...
Trend outlook by mid-September will hit $74.50, following my own ideas and not paying attention to outside noise. Trials look promising, earning looking very good, and this stock is staying out of the norm for all that I have been reading. My view is that this investment, an opioid withdrawal treatment, will be beneficial for people and in the process help to fund...
Possible entry level $42.33
target price $52.88
Stop loss $39.43
Company profile
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric...
$BTAI should see a major breakout above $12. The risk/reward setup looks promising.
About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology....
